PL1915349T5 - Sposób wytwarzania czystej bezpostaciowej rozuwastatyny wapniowej - Google Patents

Sposób wytwarzania czystej bezpostaciowej rozuwastatyny wapniowej

Info

Publication number
PL1915349T5
PL1915349T5 PL06754502T PL06754502T PL1915349T5 PL 1915349 T5 PL1915349 T5 PL 1915349T5 PL 06754502 T PL06754502 T PL 06754502T PL 06754502 T PL06754502 T PL 06754502T PL 1915349 T5 PL1915349 T5 PL 1915349T5
Authority
PL
Poland
Prior art keywords
rosuvastatin calcium
pure amorphous
preparing pure
amorphous rosuvastatin
preparing
Prior art date
Application number
PL06754502T
Other languages
English (en)
Other versions
PL1915349T3 (pl
Inventor
Zdenko Casar
Marko Zlicar
Original Assignee
Lek Pharmaceuticals D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37440674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1915349(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Pharmaceuticals D.D. filed Critical Lek Pharmaceuticals D.D.
Publication of PL1915349T3 publication Critical patent/PL1915349T3/pl
Publication of PL1915349T5 publication Critical patent/PL1915349T5/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06754502T 2005-06-24 2006-06-22 Sposób wytwarzania czystej bezpostaciowej rozuwastatyny wapniowej PL1915349T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SI200500187 2005-06-24
PCT/EP2006/006008 WO2006136408A2 (en) 2005-06-24 2006-06-22 Process for preparing pure amorphous rosuvastatin calcium
EP06754502.0A EP1915349B2 (en) 2005-06-24 2006-06-22 Process for preparing pure amorphous rosuvastatin calcium

Publications (2)

Publication Number Publication Date
PL1915349T3 PL1915349T3 (pl) 2016-05-31
PL1915349T5 true PL1915349T5 (pl) 2019-02-28

Family

ID=37440674

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06754502T PL1915349T5 (pl) 2005-06-24 2006-06-22 Sposób wytwarzania czystej bezpostaciowej rozuwastatyny wapniowej

Country Status (12)

Country Link
US (1) US8207333B2 (pl)
EP (1) EP1915349B2 (pl)
JP (1) JP5416403B2 (pl)
CN (1) CN101203496B (pl)
AU (1) AU2006261088B2 (pl)
CA (1) CA2611920C (pl)
ES (1) ES2564807T5 (pl)
HU (1) HUE027012T2 (pl)
IL (1) IL187578A0 (pl)
PL (1) PL1915349T5 (pl)
SI (1) SI1915349T1 (pl)
WO (1) WO2006136408A2 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1562912A2 (en) 2003-08-28 2005-08-17 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
CA2546701C (en) 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
KR100887264B1 (ko) 2003-12-02 2009-03-06 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 특성화를 위한 기준 표준물
ES2389565T3 (es) 2005-02-22 2012-10-29 Teva Pharmaceutical Industries Ltd. Rosuvastatina y sales de la misma carentes de alquiléter de rosuvatatina y un procedimiento para la preparación de las mismas
US9150518B2 (en) * 2005-06-24 2015-10-06 Lek Pharmaceuticals, D.D. Process for preparing amorphous rosuvastatin calcium of impurities
WO2007022488A2 (en) 2005-08-16 2007-02-22 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
JP2008539278A (ja) * 2006-09-18 2008-11-13 テバ ファーマシューティカル インダストリーズ リミティド 結晶性ロスバスタチンカルシウム
WO2008053334A2 (en) * 2006-10-31 2008-05-08 Aurobindo Pharma Limited An improved process for preparing rosuvastatin calcium
ES2385623T3 (es) * 2007-02-08 2012-07-27 Aurobindo Pharma Limited Un procedimiento mejorado para la preparación de rosuvastatina cálcica
EP2178846A1 (en) 2007-07-12 2010-04-28 Teva Pharmaceutical Industries Ltd. Rosuvastatin intermediates and their preparation
US8653265B2 (en) 2008-05-27 2014-02-18 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
WO2010035284A2 (en) * 2008-09-26 2010-04-01 Matrix Laboratories Ltd An improved process for the preparation of rosuvastatin calcium
EP2752407B1 (en) * 2009-01-14 2015-09-23 Krka Tovarna Zdravil, D.D., Novo Mesto Crystalline rosuvastatin calcium trihydrate
MX2011007478A (es) * 2009-01-15 2011-09-15 Sag Egis Gyogyszergyar Nylvanosan Muekoedoe Reszvenytarsa Proceso para la preparacion de sales de rosuvastatina.
EP2467363A1 (en) 2009-08-17 2012-06-27 Aurobindo Pharma Limited Process for the manufacture of rosuvastatin calcium using crystalline rosuvastatin ethyl ester
HU230987B1 (hu) 2010-11-29 2019-08-28 Egis Gyógyszergyár Nyrt. Eljárás nagy tisztaságú gyógyszeripari intermedierek előállítására
FR2970178B1 (fr) 2011-01-07 2014-06-20 Liliane Therese Jacquot Promedicaments pour une delivrance specifique au niveau du foie et une meilleure tolerance
CN102070537B (zh) * 2011-01-28 2012-01-11 海南美大制药有限公司 一种瑞舒伐他汀钙化合物及其新制法
WO2013046222A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited A process for the preparation of amorphous rosuvastatin calcium
CN103709107B (zh) * 2012-09-29 2016-04-20 安徽省庆云医药化工有限公司 瑞舒伐他汀甲酯的新晶型及其制备方法
CN104370827B (zh) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 瑞舒伐他汀钙化合物
JP2017512183A (ja) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
US11970482B2 (en) * 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof
CN108398501A (zh) * 2018-03-02 2018-08-14 海南通用三洋药业有限公司 一种检测瑞舒伐他汀钙有关物质的方法
CN108675931A (zh) * 2018-05-18 2018-10-19 合肥合源药业有限公司 一种低钡他汀钙及其制备方法
CN111170950A (zh) * 2020-01-16 2020-05-19 河南豫辰药业股份有限公司 一种瑞舒伐他汀钙盐的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
EP1562912A2 (en) 2003-08-28 2005-08-17 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
US20070191318A1 (en) * 2003-10-22 2007-08-16 Yatendra Kumar Process for the preparation of amorphous rosuvastatin calcium
WO2005054207A1 (en) 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
WO2005077917A1 (en) 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
WO2006035277A2 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Novel processes for preparing amorphous rosuvastatin calcium and a novel polymorphic form of rosuvastatin sodium

Also Published As

Publication number Publication date
JP5416403B2 (ja) 2014-02-12
AU2006261088B2 (en) 2012-11-08
ES2564807T3 (es) 2016-03-29
EP1915349B2 (en) 2018-09-12
US20080188504A1 (en) 2008-08-07
IL187578A0 (en) 2008-03-20
HUE027012T2 (en) 2016-10-28
CN101203496B (zh) 2011-04-20
EP1915349B1 (en) 2015-12-09
CA2611920A1 (en) 2006-12-28
WO2006136408A2 (en) 2006-12-28
JP2008543899A (ja) 2008-12-04
EP1915349A2 (en) 2008-04-30
AU2006261088A1 (en) 2006-12-28
CA2611920C (en) 2015-05-05
CN101203496A (zh) 2008-06-18
PL1915349T3 (pl) 2016-05-31
ES2564807T5 (es) 2019-02-26
US8207333B2 (en) 2012-06-26
SI1915349T1 (sl) 2016-05-31
WO2006136408A3 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
IL187578A0 (en) Process for preparing pure amorphous rosuvastatin calcium
IL187483A0 (en) Process for preparing amorphous rosuvastatin calcium free of impurities
IL183528A0 (en) Process for preparing rosuvastatin
PT1923359E (pt) Processo para a produção de frasquinhos
SI1727795T1 (sl) Postopek za pripravo atorvastatin kalcija v amorfni obliki
EP1813677A4 (en) PROCESS FOR MAKING BASIC SUBSTANCE
EP1828170A4 (en) PROCESS FOR PREPARING VORICONAZOLE
HK1119152A1 (en) Process for producing nanocrystalline
ZA200608083B (en) Process for preparing 5-methyl-2-furfural
EP1748076A4 (en) PROCESS FOR THE MANUFACTURE OF HYDROXYCARBOXYLIC ACID
TWI372145B (en) Process for preparing alkylanilides
IL182474A0 (en) Process for forming amorphous atorvastatin
IL197327A0 (en) Crystalline rosuvastatin calcium
EP1751123A4 (en) PROCESS FOR PREPARING IRBESARTAN
IL183239A0 (en) Process for preparing amorphous valsartan
IL184874A0 (en) Process for preparing protected amidines
IL185872A0 (en) Process for preparing levetiracetam
EP1930484A4 (en) PROCESS FOR PRODUCING MONOCRYSTAL
ZA200608632B (en) Process for forming amorphous atorvastatin calcium
ZA200806049B (en) Cefdinir synthesis process
EP1939301A4 (en) PROCESS FOR PRODUCING A USEFUL SUBSTANCE
IL182211A0 (en) Process for preparing purine compounds
EP1856101A4 (en) PROCESS FOR PREPARING AMORPHENE SALTS
EP1907474A4 (en) PROCESS FOR PRODUCING A POLYOLEFIN
EP1852518A4 (en) METHOD FOR PRODUCING MULTIFUNCTIONAL MATERIAL